| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jan 12, 2016Single-Use System for stone removal eliminates maintenance, reprocessing and sterilizationBoston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launch of the LithoVueTM Single-Use Digital Flexible Ureteroscope for minimally invasive endoscopic procedures to...
-
Dec 11, 2015
Final results evaluating the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate that the device provides more than 70 percent greater...
-
Nov 19, 2015First Implants Occur in Europe, Commencing Limited Market Release
Boston Scientific (NYSE: BSX) today announced that the first implants of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device – the latest generation of the WATCHMAN Device –...
-
Nov 9, 2015Topline data confirming peri-procedural safety of left atrial appendage (LAA) occlusion with the WATCHMAN™ Left Atrial Appendage (LAA) Closure device was presented in an oral session during the American Heart Association (AHA) Scientific Sessions.
This is the first study to collect real-world WATCHMAN LAA Closure Device experience outside of selected populations in randomized trials. Results from the prospective, multi-centre EWOLUTION...
-
Sep 28, 2015A media briefing with a difference: join us for this interactive session on severe asthma. Hear from Europe’s leading experts in asthma and visit our information stations to bring the story to life.
September 28, 2015, 18:30 – 20:00 Wyndham Apollo Hotel Amsterdam (15 minutes from the ERS Congress Venue, the Amsterdam RAI Exhibition and Convention Centre) Agenda 18:30 Welcome and scene...
-
Sep 28, 2015Work, social and family life all affected by severe asthma, many people report feelings of anxiety, depression and isolation as well
Boston Scientific today revealed results of a comprehensive survey which shows the true burden of severe asthma and the daily challenges faced by people with asthma in Europe. Uncovering Asthma, a...
-
Sep 28, 2015MAJESTIC Trial Data Support Strong Safety Profile with Low Target Lesion Revascularization Rate
New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System reflect a primary patency rate1 of more...
-
Sep 26, 2015
Results from clinical trials evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System continue to show this advanced transcatheter aortic valve implantation (TAVI) therapy delivers...
-
Sep 10, 2015System includes first directional lead with current steering and expanded programming flexibility
Boston Scientific (NYSE: BSX) has received CE Mark for the Vercise™ Primary Cell (PC) Deep Brain Stimulation (DBS) System. The Vercise PC System is intended to provide precise neural targeting...
-
Aug 31, 2015
Boston Scientific welcomes the updated ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death announced during ESC Congress 2015, the...